Evidence map›Paper›PMID 40769770›Full record

ArticleVox sanguinis2025

In vitro quality of whole blood-derived red cell concentrates collected, processed and stored in a blood bag set plasticized with di (2-ethylhexyl) terephthalate.

Tatiana Stephenson, Anita Howell, Carly Olafson, Chryslain Sumian, Stefan Reichenberg, Quentin Brebant, Ken McTaggart, Geraldine M Walsh

Abstract read
In one paragraph

Article in Vox sanguinis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tatiana StephensonProduct and Process Development, Canadian Blood Services, Vancouver, British Columbia, Canada.
Anita HowellProduct and Process Development, Canadian Blood Services, Edmonton, Alberta, Canada.
Carly OlafsonProduct and Process Development, Canadian Blood Services, Edmonton, Alberta, Canada.
Chryslain SumianClinical Regulatory Affairs, Macopharma, Mouvaux, France.
Stefan ReichenbergClinical Regulatory Affairs, Macopharma, Mouvaux, France.
Quentin BrebantResearch and Development, Macopharma, Mouvaux, France.
Ken McTaggartProduct and Process Development, Canadian Blood Services, Ottawa, Ontario, Canada.
Geraldine M WalshProduct and Process Development, Canadian Blood Services, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0009-0004-1433-7357

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesDue to toxicity concerns, di(2-ethylhexyl) phthalate (DEHP)-the most used plasticizer in polyvinyl chloride (PVC) whole blood (WB) collection and processing bag sets-will be effectively prohibited in medical devices in Europe from 2030. Removal of DEHP will primarily impact the in vitro quality of red blood cell (RBC) concentrates (RCCs) and DEHP-free sets with alternate additive solutions (ASs) that better preserve RBCs in the absence of DEHP are being developed. This study compared the in vitro quality of RCCs from di (2-ethylhexyl) terephthalate (DEHT)/phosphate-adenine-glucose-guanosine-saline-mannitol (PAGGSM) and DEHP/saline-adenine-glucose-mannitol (SAGM) sets. MATERIALS AND

methodsWB was collected into citrate-phosphate-dextrose (CPD) in either 500-mL DEHP/SAGM (n = 37) or prototype 475-mL DEHT/PAGGSM bag sets (n = 29). Leucoreduced (LR)-RCCs were produced using semi-automated top/bottom processing within 24 h of collection. RBC quality, including haemolysis, supernatant metabolic parameters and RBC deformability, was measured on D43 (1-day after expiry).

resultsAll RCCs in the study had haemolysis <0.8%, and there was no statistically significant difference between haemolysis in DEHT/PAGGSM and DEHP/SAGM RCC (p = 0.083). Tolerance bound analysis indicated that RCCs in DEHT/PAGGSM produced using Canadian Blood Services' main production method would meet current Canadian Standards Association (CSA) CAN/CSA-Z902:25 quality control (QC) requirements for RCCs. There were some differences in metabolic in vitro quality measures, and RBCs in DEHT/PAGGSM were slightly less deformable (lower maximum elongation index [EI

conclusionRBCs have acceptable in vitro quality at expiry in DEHT/PAGGSM, supporting a 42-day shelf life.

Indexed as

Blood PreservationDiethylhexyl PhthalateErythrocytesPlasticizersHemolysisHumansDiethylhexyl PhthalatePlasticizersadditive solutionsDEHPDEHTin vitroqualityRCC

Identifiers

PMID40769770
PMCPMC12602130

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.